Symbols

DYAI

Dyadic International·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 3

Bearish signal 2

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

Ample Liquidity

Significant Revenue Decline

Significant Net Income Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About DYAI

Dyadic International, Inc.

A global biotech company that develops enzymes and other proteins for bioenergy, bio-basedhemicals, and biopharmaceuticals

Industry

Biological Technology

Established Date

Listing Date

04/17/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.dyadic.com

Security Type

Common stock

Office address

1044 North U.S, Highway One, Suite 201 , Jupiter, Florida 33477

Business

Introduction

Dyadic International, Inc., was incorporated in Delaware in September 2002. The company is a global biotechnology platform company headquartered in Jupiter, Florida, with operations in the United States, a satellite office in the Netherlands, and corporate activities utilizing multiple third-party consultants and research organizations. Over the past two decades, the company has developed a gene expression platform for the production of commercial quantities of industrial enzymes and proteins, and has previously licensed the technology to third parties such as Abengoa Bioenergy SA, BASF SE, Codexis, Inc., for industrial applications. This technology is based on the Thermothelomyces heterothallica fungus named C1 by the company.

Earnings Call

Q2/2025

Estimate EPS--

Actual EPS-0.06

Estimate Revenue600.00K

Actual Revenue966.63K

Dyadic International's Q2 2025: Navigating Contradictions in Cash Burn, Revenue Growth, and Market Focus

Aug 13,2025 07:57·
Earnings Decrypt

Company Financials

EPS

DYAI has released its 2025 Q3 earnings. EPS was reported at -0.06, versus the expected -0.04, missing expectations. The chart below visualizes how DYAI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

DYAI has released its 2025 Q3 earnings report, with revenue of 1.16M, reflecting a YoY change of -40.50%, and net profit of -1.98M, showing a YoY change of -871.20%. The Sankey diagram below clearly presents DYAI's revenue sources and cost distribution.